Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

W Joseph

Showing results (511-520 of 531) with videos related to

Pageof 54
Sort By:
Lancet (London, England)|July 19, 2014
Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trialCaroline Robert, Antoni Ribas, Jedd D Wolchok, et al.
European Urology|April 7, 2021
A Living, Interactive Systematic Review and Network Meta-analysis of First-line Treatment of Metastatic Renal Cell CarcinomaIrbaz Bin Riaz, Huan He, Alexander J Ryu, et al.
Nature|January 11, 2018
High response rate to PD-1 blockade in desmoplastic melanomasZeynep Eroglu, Jesse M Zaretsky, Siwen Hu-Lieskovan, et al.
The New England Journal of Medicine|June 4, 2013
Safety and tumor responses with lambrolizumab (anti-PD-1) in melanomaOmid Hamid, Caroline Robert, Adil Daud, et al.
The Lancet. Rheumatology|February 1, 2024
Mycophenolate mofetil withdrawal in patients with systemic lupus erythematosus: a multicentre, open-label, randomised controlled trialEliza F Chakravarty, Tammy Utset, Diane L Kamen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 20, 2018
Quantitative Spatial Profiling of PD-1/PD-L1 Interaction and HLA-DR/IDO-1 Predicts Improved Outcomes of Anti-PD-1 Therapies in Metastatic MelanomaDouglas B Johnson, Jennifer Bordeaux, Ju Young Kim, et al.
JAMA|April 20, 2016
Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced MelanomaAntoni Ribas, Omid Hamid, Adil Daud, et al.
European Journal of Pediatrics|February 1, 2000
Manifestations and treatment of Schimke immuno-osseous dysplasia: 14 new cases and a review of the literatureC F Boerkoel, S O'Neill, J L André, et al.
Lancet (London, England)|March 9, 2016
Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trialJonathan E Rosenberg, Jean Hoffman-Censits, Tom Powles, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|April 9, 2019
Cutaneous Melanoma, Version 2.2019, NCCN Clinical Practice Guidelines in OncologyDaniel G Coit, John A Thompson, Mark R Albertini, et al.
Pageof 54

Showing results (511-520 of 531) with videos related to

Sort By:
Pageof 54
Lancet (London, England)|July 19, 2014
Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trialCaroline Robert, Antoni Ribas, Jedd D Wolchok, et al.
European Urology|April 7, 2021
A Living, Interactive Systematic Review and Network Meta-analysis of First-line Treatment of Metastatic Renal Cell CarcinomaIrbaz Bin Riaz, Huan He, Alexander J Ryu, et al.
Nature|January 11, 2018
High response rate to PD-1 blockade in desmoplastic melanomasZeynep Eroglu, Jesse M Zaretsky, Siwen Hu-Lieskovan, et al.
The New England Journal of Medicine|June 4, 2013
Safety and tumor responses with lambrolizumab (anti-PD-1) in melanomaOmid Hamid, Caroline Robert, Adil Daud, et al.
The Lancet. Rheumatology|February 1, 2024
Mycophenolate mofetil withdrawal in patients with systemic lupus erythematosus: a multicentre, open-label, randomised controlled trialEliza F Chakravarty, Tammy Utset, Diane L Kamen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 20, 2018
Quantitative Spatial Profiling of PD-1/PD-L1 Interaction and HLA-DR/IDO-1 Predicts Improved Outcomes of Anti-PD-1 Therapies in Metastatic MelanomaDouglas B Johnson, Jennifer Bordeaux, Ju Young Kim, et al.
JAMA|April 20, 2016
Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced MelanomaAntoni Ribas, Omid Hamid, Adil Daud, et al.
European Journal of Pediatrics|February 1, 2000
Manifestations and treatment of Schimke immuno-osseous dysplasia: 14 new cases and a review of the literatureC F Boerkoel, S O'Neill, J L André, et al.
Lancet (London, England)|March 9, 2016
Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trialJonathan E Rosenberg, Jean Hoffman-Censits, Tom Powles, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|April 9, 2019
Cutaneous Melanoma, Version 2.2019, NCCN Clinical Practice Guidelines in OncologyDaniel G Coit, John A Thompson, Mark R Albertini, et al.
Pageof 54